Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
NEULANDLABNSENeuland Laboratories Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 6 Oct, 2025 · 15:30 IST

Postal ballot seeks approval for leadership re-designations

Management Changes View source PDFExplain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.3%Reaction day
₹15106.00
prior close
₹15162.00
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+4.2% vs market
Pharmaceuticals peers, median of 153sector-0.5%+4.7% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Smallcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.2
10m
+0.0
15m
+0.3
30m
+0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.3+0.1+4.2-0.5+4.7
Next day
+2.4-0.4+2.8-0.9+3.3
2d
+3.9-0.1+4.0-0.2+4.1
3d
+8.0+0.5+7.5+0.0+8.0
4d
+7.3+0.2+7.1-0.5+7.8
5d
+7.4-0.7+8.1-1.3+8.7
1w
+6.9+0.5+6.4-1.1+8.0
15d
+2.1+2.3-0.2-0.9+3.0
1m
+17.6-0.1+17.7-2.9+20.5
2m
+6.3-5.3+11.7-7.2+13.5
3m
+0.2-1.3+1.5-5.9+6.1
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shareholders are asked to approve two leadership changes by remote e-voting, effective April 1, 2026. Davuluri Sucheth Rao would become Executive Vice Chairman, moving away from the CEO role, and Davuluri Saharsh Rao would become Chief Executive Officer and Managing Director. Their tenure and other terms remain unchanged. Voting runs October 7 to November 5, 2025.

Likely market impact

No immediate financial impact is disclosed. The role split may improve accountability, but shareholder approval is required and no pay or tenure change is proposed.